{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:48:46Z","timestamp":1777632526647,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"crossref","award":["2017480"],"award-info":[{"award-number":["2017480"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40271-025-00796-w","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:57:08Z","timestamp":1765987028000},"page":"435-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Formative Research in the Codesign of a Discrete Choice Experiment with Patients with Myasthenia Gravis: Selecting and Refining Attributes, Levels and Scenarios"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5535-6053","authenticated-orcid":false,"given":"Gozde","family":"Aydin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7180-321X","authenticated-orcid":false,"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3882-2531","authenticated-orcid":false,"given":"Dennis","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-7003","authenticated-orcid":false,"given":"Anneke","family":"Van der Walt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0169-3350","authenticated-orcid":false,"given":"Stephen","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-9303","authenticated-orcid":false,"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Windle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Bergin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2685-3875","authenticated-orcid":false,"given":"Laura","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"796_CR1","unstructured":"Lindsay KW, Bone I, Fuller G. Neurology and neurosurgery illustrated E-book: neurology and neurosurgery illustrated E-book. ed. Elsevier Health Sciences; 2010."},{"key":"796_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J Neurol. 2016;263:1473\u201394.","journal-title":"J Neurol"},{"key":"796_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/bs.irn.2025.05.001","volume":"183","author":"VL Salutto","year":"2025","unstructured":"Salutto VL, Shin HY, Cea G. Traditional treatments and different geographical approaches. Int Rev Neurobiol. 2025;183:83\u2013112.","journal-title":"Int Rev Neurobiol"},{"issue":"9","key":"796_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s40267-024-01095-4","volume":"40","author":"C Fenton","year":"2024","unstructured":"Fenton C, Kang C. Several more myasthenia gravis therapy options now available. Drugs Ther Perspect. 2024;40(9):350\u20132.","journal-title":"Drugs Ther Perspect"},{"issue":"5","key":"796_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"issue":"2","key":"796_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024;20(2):84\u201398.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"796_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","volume":"13","author":"C Heatwole","year":"2011","unstructured":"Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011;13(2):85\u201394.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"796_CR8","first-page":"517","volume":"30","author":"P-W Lien","year":"2024","unstructured":"Lien P-W, Joshi M, Tice JA, Agboola F, Nikitin D, Withanawasam V, et al. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. J Manag Care Spec Pharm. 2024;30(6):517\u201327.","journal-title":"J Manag Care Spec Pharm"},{"key":"796_CR9","unstructured":"Pharmaceutical Benefits Advisory Committee. Myasthenia Gravis Stakeholder Meeting Outcome Statement of subordinate document. In: Myasthenia Gravis Stakeholder Meeting Outcome Statement of web site. PBAC; 2024. Available from: https:\/\/m.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/pbac-stakeholder-meetings\/Myasthenia%20Gravis%20Stakeholder%20Meeting%20Outcome%20Statement.docx. Accessed."},{"key":"796_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/978-981-10-5251-4_93","volume-title":"Handbook of research methods in health social sciences","author":"M Howell","year":"2019","unstructured":"Howell M, Howard K. Eliciting preferences from choices: discrete choice experiments. In: Handbook of research methods in health social sciences. Berlin: Springer; 2019. p. 623\u201344."},{"issue":"7","key":"796_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hec.1193","volume":"16","author":"MT King","year":"2007","unstructured":"King MT, Hall J, Lancsar E, Fiebig D, Hossain I, Louviere J, et al. Patient preferences for managing asthma: results from a discrete choice experiment. Health Econ. 2007;16(7):703\u201317.","journal-title":"Health Econ"},{"issue":"7436","key":"796_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/bmj.37972.497234.44","volume":"328","author":"M Sculpher","year":"2004","unstructured":"Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients\u2019 preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ. 2004;328(7436):382.","journal-title":"BMJ"},{"issue":"6","key":"796_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3109\/14659891.2015.1118563","volume":"21","author":"TM Helter","year":"2016","unstructured":"Helter TM, Boehler CEH. Developing attributes for discrete choice experiments in health: a systematic literature review and case study of alcohol misuse interventions. J Subst Use. 2016;21(6):662\u20138.","journal-title":"J Subst Use"},{"key":"796_CR14","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S38408","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, van Durme C, Geusens P, Dellaert BG, Dirksen CD, van der Weijden T, et al. Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adher. 2013. https:\/\/doi.org\/10.2147\/PPA.S38408.","journal-title":"Patient Prefer Adher"},{"issue":"3","key":"796_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/0272989X16683934","volume":"37","author":"C Vass","year":"2017","unstructured":"Vass C, Rigby D, Payne K. The role of qualitative research methods in discrete choice experiments: a systematic review and survey of authors. Med Decis Mak. 2017;37(3):298\u2013313.","journal-title":"Med Decis Mak"},{"key":"796_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40271-019-00401-x","volume":"13","author":"IL Hollin","year":"2020","unstructured":"Hollin IL, Craig BM, Coast J, Beusterien K, Vass C, DiSantostefano R, et al. Reporting formative qualitative research to support the development of quantitative preference study protocols and corresponding survey instruments: guidelines for authors and reviewers. Patient. 2020;13:121\u201336.","journal-title":"Patient"},{"issue":"2","key":"796_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1755-5345(13)70050-2","volume":"5","author":"ME Kl\u00f8jgaard","year":"2012","unstructured":"Kl\u00f8jgaard ME, Bech M, S\u00f8gaard R. Designing a stated choice experiment: the value of a qualitative process. J Choice Model. 2012;5(2):1\u201318.","journal-title":"J Choice Model"},{"issue":"6","key":"796_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jval.2023.01.002","volume":"26","author":"Z F\u00f6hn","year":"2023","unstructured":"F\u00f6hn Z, Nicolet A, Marti J, Kaufmann C, Balthasar A. Stakeholder engagement in designing attributes for a discrete choice experiment with policy implications: an example of 2 Swiss studies on healthcare delivery. Value Health. 2023;26(6):925\u201333.","journal-title":"Value Health"},{"key":"796_CR19","doi-asserted-by":"crossref","unstructured":"Mansfield C, Ho K-A, Pierce A, Vass C, Liu X, Boroojerdi B, et al., editors. Patient preferences for myasthenia gravis treatments: a Discrete-choice Experiment (P4-11.013). Neurology. 2024. AAN Enterprises.","DOI":"10.1212\/WNL.0000000000206306"},{"key":"796_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-3-319-67144-4_15","volume":"1031","author":"L Perestelo-P\u00e9rez","year":"2017","unstructured":"Perestelo-P\u00e9rez L, Rivero-Santana A, Abt-Sacks A, Toledo-Chavarri A, Brito N, \u00c1lvarez-P\u00e9rez Y, et al. Patient empowerment and involvement in research. In: Posada de la Paz M, Taruscio D, Groft SC, editors. Rare diseases epidemiology update and overview; 2017, vol. 1031, p. 249\u201364.","journal-title":"Adv Exp Med Biol"},{"key":"796_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-018-3305-5","volume":"18","author":"A De Br\u00fan","year":"2018","unstructured":"De Br\u00fan A, Flynn D, Ternent L, Price CI, Rodgers H, Ford GA, et al. A novel design process for selection of attributes for inclusion in discrete choice experiments: case study exploring variation in clinical decision-making about thrombolysis in the treatment of acute ischaemic stroke. BMC Health Serv Res. 2018;18:1\u201314.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"796_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2023;12(1):107\u201328.","journal-title":"Neurol Ther"},{"key":"796_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jocn.2023.09.023","volume":"118","author":"J Sansoni","year":"2023","unstructured":"Sansoni J, Menon N, Viali L, White S, Vucic S. Clinical features, treatments, their impact, and quality of life for myasthenia gravis patients in Australia. J Clin Neurosci. 2023;118:16\u201322.","journal-title":"J Clin Neurosci"},{"key":"796_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10742-014-0121-1","volume":"14","author":"SS McMillan","year":"2014","unstructured":"McMillan SS, Kelly F, Sav A, Kendall E, King MA, Whitty JA, et al. Using the nominal group technique: how to analyse across multiple groups. Health Serv Outcomes Res Methodol. 2014;14:92\u2013108.","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"796_CR25","first-page":"655","volume":"38","author":"SS McMillan","year":"2016","unstructured":"McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38:655\u201362.","journal-title":"Int J Clin Pharm"},{"key":"796_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jclinepi.2021.08.008","volume":"139","author":"SI Harb","year":"2021","unstructured":"Harb SI, Tao L, Pel\u00e1ez S, Boruff J, Rice DB, Shrier I. Methodological options of the nominal group technique for survey item elicitation in health research: a scoping review. J Clin Epidemiol. 2021;139:140\u20138.","journal-title":"J Clin Epidemiol"},{"key":"796_CR27","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s00415-018-8995-4","volume":"265","author":"T Alekseeva","year":"2018","unstructured":"Alekseeva T, Gavrilov Y, Kreis O, Valko P, Weber K, Valko Y. Fatigue in patients with myasthenia gravis. J Neurol. 2018;265:2312\u201321.","journal-title":"J Neurol"},{"key":"796_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00023210-200721060-00004","volume":"21","author":"IB Kulaksizoglu","year":"2007","unstructured":"Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs. 2007;21:473\u201381.","journal-title":"CNS Drugs"},{"issue":"9","key":"796_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/00207454.2022.2031183","volume":"133","author":"X Zhou","year":"2023","unstructured":"Zhou X, Cao S, Hou J, Gui T, Zhu F, Xue Q. Association between myasthenia gravis and cognitive disorders: a PRISMA-compliant meta-analysis. Int J Neurosci. 2023;133(9):987\u201398.","journal-title":"Int J Neurosci"},{"key":"796_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4337\/9781800375635.00013","volume-title":"Handbook of choice modelling","author":"MC Bliemer","year":"2024","unstructured":"Bliemer MC, Rose JM. Designing and conducting stated choice experiments of section. In: Hess S, Daly A, editors. Handbook of choice modelling. Edward Elgar Publishing; 2024. p. 172\u2013205."},{"issue":"3","key":"796_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10742-014-0121-1","volume":"14","author":"SS McMillan","year":"2014","unstructured":"McMillan SS, Kelly F, Sav A, Kendall E, King MA, Whitty JA, et al. Using the nominal group technique: how to analyse across multiple groups. Health Serv Outcomes Res Methodol. 2014;14(3):92\u2013108.","journal-title":"Health Serv Outcomes Res Methodol"},{"issue":"7","key":"796_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219905","volume":"14","author":"M Trapero-Bertran","year":"2019","unstructured":"Trapero-Bertran M, Rodr\u00edguez-Mart\u00edn B, L\u00f3pez-Bastida J. What attributes should be included in a discrete choice experiment related to health technologies? A systematic literature review. PLoS ONE. 2019;14(7):e0219905.","journal-title":"PLoS ONE"},{"issue":"9","key":"796_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","volume":"32","author":"MD Clark","year":"2014","unstructured":"Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883\u2013902.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"796_CR34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G","volume":"23","author":"M Sandelowski","year":"2000","unstructured":"Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):334\u201340.","journal-title":"Res Nurs Health"},{"key":"796_CR35","first-page":"426","volume":"426","author":"N King","year":"2012","unstructured":"King N. Doing template analysis. Qual Organ Res Core Methods Curr Chall. 2012;426:426\u201350.","journal-title":"Qual Organ Res Core Methods Curr Chall."},{"key":"796_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.vhri.2021.06.005","volume":"27","author":"P Chiwire","year":"2022","unstructured":"Chiwire P, Evers SM, Mahomed H, Hiligsmann M. Identification and prioritization of attributes for a discrete choice experiment using the nominal group technique: patients\u2019 choice of public health facilities in Cape Town, South Africa. Value Health Reg Issues. 2022;27:90\u20138.","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"796_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/2381468319837925","volume":"4","author":"C Somers","year":"2019","unstructured":"Somers C, Chimonas S, McIntosh E, Kaltenboeck A, Briggs A, Bach P. Using nominal group technique to identify key attributes of oncology treatments for a discrete choice experiment. MDM Policy Pract. 2019;4(1):2381468319837925.","journal-title":"MDM Policy Pract"},{"issue":"1","key":"796_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5694\/mja14.00002","volume":"201","author":"TC Hoffmann","year":"2014","unstructured":"Hoffmann TC, Legare F, Simmons MB, McNamara K, McCaffery K, Trevena LJ, et al. Shared decision making: what do clinicians need to know and why should they bother? Med J Aust. 2014;201(1):35\u20139.","journal-title":"Med J Aust"},{"key":"796_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2023.107825","volume":"114","author":"S Birkeland","year":"2023","unstructured":"Birkeland S, Bismark M, Barry MJ, M\u00f6ller S. \u2018My doctor should decide\u2019\u2013predictors for healthcare users\u2019 stated preferences regarding medical decision-making. Patient Educ Couns. 2023;114:107825.","journal-title":"Patient Educ Couns"},{"issue":"12","key":"796_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70230","volume":"7","author":"G Geonnotti","year":"2024","unstructured":"Geonnotti G, Pesa J, Peters W, Taylor M, Choudhry Z, Falope O, et al. Design of and early insights from a Generalized Myasthenia Gravis Patient Engagement Research Council. Health Sci Rep. 2024;7(12):e70230.","journal-title":"Health Sci Rep"},{"issue":"4","key":"796_CR41","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40120-024-00617-6","volume":"13","author":"N Kawaguchi","year":"2024","unstructured":"Kawaguchi N, Tsuda K, Tanaka N, Kerstens R, Harada D. Myasthenia gravis disease burden and its impact on satisfaction with life: a qualitative survey of patients\u2019 perspectives in Japan. Neurol Ther. 2024;13(4):1099\u2013113.","journal-title":"Neurol Ther"},{"issue":"12","key":"796_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088813","volume":"14","author":"J-P Camdessanch\u00e9","year":"2024","unstructured":"Camdessanch\u00e9 J-P, Sacconi S, Archer A, Boulanger P, Crochard A, Bertocchio J-P, et al. SPOON: an observational, cross-sectional study of perceptions and expectations of adults with generalised myasthenia gravis in France. BMJ Open. 2024;14(12):e088813.","journal-title":"BMJ Open"},{"issue":"2","key":"796_CR43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s13760-023-02187-0","volume":"123","author":"R Mercelis","year":"2023","unstructured":"Mercelis R, Alonso-Jim\u00e9nez A, Van Schil P. Current management of myasthenia gravis in Belgium: a single-center experience. Acta Neurol Belg. 2023;123(2):375\u201384.","journal-title":"Acta Neurol Belg"},{"key":"796_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-019-1573-2","volume":"19","author":"ED Bacci","year":"2019","unstructured":"Bacci ED, Coyne KS, Poon J-L, Harris L, Boscoe AN. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19:1\u201313.","journal-title":"BMC Neurol"},{"issue":"6","key":"796_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40271-025-00746-6","volume":"18","author":"A Livingstone","year":"2021","unstructured":"Livingstone A, Engel L, White V, De Silva D, Bucholc J, Murphy A, et al. Preferences for telephone cancer information and support in people with cancer and carers: attribute and level selection for a discrete choice experiment. Patient. 2025;18(6):645\u2013660.","journal-title":"Patient"},{"key":"796_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.113822","volume":"276","author":"MG Genie","year":"2021","unstructured":"Genie MG, Ryan M, Krucien N. To pay or not to pay? Cost information processing in the valuation of publicly funded healthcare. Soc Sci Med. 2021;276:113822.","journal-title":"Soc Sci Med"},{"key":"796_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-024-00696-5","author":"JA Whitty","year":"2024","unstructured":"Whitty JA, Lancsar E, De Abreu Lourenco R, Howard K, Stolk EA. Putting the choice in choice tasks: incorporating preference elicitation tasks in health preference research. Patient. 2024. https:\/\/doi.org\/10.1007\/s40271-024-00696-5.","journal-title":"Patient"},{"issue":"2","key":"796_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.36253\/web-7978","volume":"9","author":"F Boncinelli","year":"2020","unstructured":"Boncinelli F, Contini C, Gerini F, Romano C, Scozzafava G, Casini L. The role of context definition in choice experiments: a methodological proposal based on customized scenarios. Wine Econ Policy. 2020;9(2):49\u201362.","journal-title":"Wine Econ Policy"},{"issue":"6","key":"796_CR49","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40271-021-00528-w","volume":"14","author":"SM Carter","year":"2021","unstructured":"Carter SM, Shih P, Williams J, Degeling C, Mooney-Somers J. Conducting qualitative research online: challenges and solutions. Patient. 2021;14(6):711\u20138.","journal-title":"Patient"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-025-00796-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:08:25Z","timestamp":1777435705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-025-00796-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["796"],"URL":"https:\/\/doi.org\/10.1007\/s40271-025-00796-w","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stephen Reddel: Over the last 5 years, funds including but not limited to travel support, honoraria, trial payments, research and\/or clinical support to the neurology department or academic projects of which I am a member have been received from the following bodies, entities, organisations and charities: NHMRC, MRFF, NBA, Myasthenia Alliance Australia, Beeren Foundation; and from the following pharmaceutical\/biological companies: Alexion, Argenx, Biogen, CSL, Genzyme, Grifols, Jannsen, Merck, Novartis, Roche, Sandoz, Sanofi, UCB. Additional interests and potential conflicts of interest include: Co-founder\/shareholder of RxPx health, National IVIG Governance Advisory Council & Specialist Working Group Australia (Neurology) (paid), Australian Medical Services Advisory Committee ad-hoc sub-committee on IVIG (paid), Australian Technical Advisory Group on Immunisation Varicella Zoster working party (unpaid), public salary as a staff specialist neurologist from Concord Hospital Sydney Local Health District (paid), private billings from patients and Medicare Australia reimbursement as a private practice neurologist (paid), medical advisor (unpaid) to various patient and advocacy groups. A. Van der Walt has served on advisory boards and receives unrestricted research grants from Novartis, Biogen, Merck and Roche. She has received speaker's honoraria and travel support from Novartis, Roche and Merck. She receives grant support from the National Health and Medical Research Council of Australia and MS Research Australia. K. Buzzard has received speaker's honoraria and\/or education support from Biogen, Teva, Novartis, Genzyme-Sanofi, Roche, Merck, Argenx, UCB, CSL and Alexion; and has been a member of advisory boards for Merck, Alexion, Argenx, UCB, CSL and Biogen. The other authors have no COI to declare related to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Human Research Ethics Committee of Monash University (Ethics approval number: 40891) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants gave written informed consent to participate in the research and for their de-identified data to be used in publications.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent for publication"}},{"value":"The data that support the findings of this study are available from the authors upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to this manuscript\u2019s concept development, data acquisition, analysis, writing and editing. GA: conceptualisation, methodology, data acquisition, formal analysis, interpretation, writing original draft, writing and project administration. XZ: conceptualisation, methodology, data acquisition, formal analysis, interpretation. DP: conceptualisation, methodology, data acquisition, interpretation. AWdV, SR and KB: conceptualisation, interpretation. NW, SW and CB: conceptualisation, data acquisition, interpretation. LF: conceptualisation, methodology, interpretation and writing. All authors reviewed, edited and approved the final version of this manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}